Fungal otitis externa is an infection of the outer ear canal. Fungal otitis externa mostly affects people who live in warm or tropical areas. It also often affects people who swim frequently, live with diabetes, or have other chronic medical and skin conditions. The Symptoms of otitis externa include ear pain, itchiness in the ear canal, a discharge of liquid or pus from the ear and some degree of temporary hearing loss. Otitis externa is relatively common. It's estimated that around 1 in 10 people will be affected by it at some point in their lives.
Market Dynamics
Robust product pipeline for the treatment of fungal otitis externa which are expected to launch during the forecast period is anticipated to drive the growth of the global fungal otitis externa market. For instance, on July 8, 2020, Hill Dermaceuticals, Inc., a U.S.-based pharmaceutical company, initiated a phase II/III Study of the efficacy and safety of miconazole oil versus vehicle oil in the treatment of otomycosis, followed by an open-label safety evaluation. The study is estimated to be completed by December 2021. Furthermore, increasing prevalence of fungal otitis externa is expected to lead to high demand for various treatment therapy. For instance, according to the Sandoz, a subsidiary of Novartis AG, over 80% of the U.S. children experience at least one ear infection by their third birthday. Moreover, according to the American Academy of Family Physicians, the Fungi are identified in about 10% of cases of otitis externa. The most common pathogen is Aspergillus (80 to 90% of cases), followed by Candida.
Key features of the study:
- This report provides in-depth analysis of the global fungal otitis externa market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global fungal otitis externa market based on the following parameters – Company Highlights, Product Portfolio, Key Highlights, Financial Performance, Market Strategies
- Key companies covered as a part of this study include Novartis, Bayer AG, Sanofi, GlaxoSmithKline plc., AbbVie, Par Pharmaceutical, Inc., Hi-Tech Pharma, Actavis Mid-Atlantic, Hill Dermaceuticals Inc, NuLife Pharmaceuticals, Glenmark Pharmaceuticals Limited, Pfizer Inc., Janssen Pharmaceutical, McNeil Consumer Healthcare, Mylan N.V., and Salvat Laboratories
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global fungal otitis externa market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fungal otitis externa market
Detailed Segmentation:
- Global Fungal Otitis Externa Market, By Drug Type:
- Ear Drops
- Clotrimazole
- Fluconazole
- Acetic Acid (2%)
- Oral Medications
- Topical Medications
- Late Stage Pipeline Drugs
- Global Fungal Otitis Externa Market, By Fungus Type:
- Global Fungal Otitis Externa Market, By Route of Administration:
- Global Fungal Otitis Externa Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Fungal Otitis Externa Market, By Region:
- North America
- By Drug Type:
- Ear Drops
- Clotrimazole
- Fluconazole
- Acetic Acid (2%)
- Oral Medications
- Topical Medications
- Late Stage Pipeline Drugs
- By Fungus Type:
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Type:
- Ear Drops
- Clotrimazole
- Fluconazole
- Acetic Acid (2%)
- Oral Medications
- Topical Medications
- Late Stage Pipeline Drugs
- By Fungus Type:
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type:
- Ear Drops
- Clotrimazole
- Fluconazole
- Acetic Acid (2%)
- Oral Medications
- Topical Medications
- Late Stage Pipeline Drugs
- By Fungus Type:
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type:
- Ear Drops
- Clotrimazole
- Fluconazole
- Acetic Acid (2%)
- Oral Medications
- Topical Medications
- Late Stage Pipeline Drugs
- By Fungus Type:
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Type:
- Ear Drops
- Clotrimazole
- Fluconazole
- Acetic Acid (2%)
- Oral Medications
- Topical Medications
- Late Stage Pipeline Drugs
- By Fungus Type:
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type:
- Ear Drops
- Clotrimazole
- Fluconazole
- Acetic Acid (2%)
- Oral Medications
- Topical Medications
- Late Stage Pipeline Drugs
- By Fungus Type:
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Novartis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Sanofi
- GlaxoSmithKline plc
- AbbVie
- Par Pharmaceutical, Inc
- Hi-Tech Pharma
- Actavis Mid-Atlantic
- Hill Dermaceuticals Inc
- NuLife Pharmaceuticals
- Glenmark Pharmaceuticals Limited
- Pfizer Inc
- Janssen Pharmaceutical
- McNeil Consumer Healthcare
- Mylan N.V.
- Salvat Laboratories
“*” marked represents similar segmentation in other categories in the respective section.
